Literature DB >> 27746627

Comments: Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy against HCV Infection: Update 2016.

Sanjay Hadigal1.   

Abstract

Year:  2016        PMID: 27746627      PMCID: PMC5052423          DOI: 10.1016/j.jceh.2016.08.003

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


× No keyword cloud information.
  3 in total

Review 1.  Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Authors: 
Journal:  Hepatology       Date:  2015-08-04       Impact factor: 17.425

Review 2.  Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.

Authors:  Pankaj Puri; Vivek A Saraswat; Radha K Dhiman; Anil C Anand; Subrat K Acharya; Shivaram P Singh; Yogesh K Chawla; Deepak N Amarapurkar; Ajay Kumar; Anil Arora; Vinod K Dixit; Abraham Koshy; Ajit Sood; Ajay Duseja; Dharmesh Kapoor; Kaushal Madan; Anshu Srivastava; Ashish Kumar; Manav Wadhawan; Amit Goel; Abhai Verma; Gaurav Pandey; Rohan Malik; Swastik Agrawal
Journal:  J Clin Exp Hepatol       Date:  2016-07-02

3.  Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Authors:  Michael Charlton; Gregory T Everson; Steven L Flamm; Princy Kumar; Charles Landis; Robert S Brown; Michael W Fried; Norah A Terrault; Jacqueline G O'Leary; Hugo E Vargas; Alexander Kuo; Eugene Schiff; Mark S Sulkowski; Richard Gilroy; Kymberly D Watt; Kimberly Brown; Paul Kwo; Surakit Pungpapong; Kevin M Korenblat; Andrew J Muir; Lewis Teperman; Robert J Fontana; Jill Denning; Sarah Arterburn; Hadas Dvory-Sobol; Theo Brandt-Sarif; Phillip S Pang; John G McHutchison; K Rajender Reddy; Nezam Afdhal
Journal:  Gastroenterology       Date:  2015-05-15       Impact factor: 22.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.